Page 71 - CJO_F17_GLAUCOMA_SUPPLEMENT

MANAGING OPEN ANGLE GLAUCOMA

ophthalmology. 2017;17(1):78.
374. Angmo D, Wadhwani M, Velpandian T, Kotnal A, Sihota R, Dada
T. Evaluation of physical properties and dose equivalency of
generic versus branded latanoprost formulations. Int Ophthalmol.
2017;37(2):423-428.
375. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in
adults. Cochrane Database Syst Rev. 2013;2(2).
376. Lusthaus JA, Goldberg I. Emerging drugs to treat glaucoma: Target-
ing prostaglandin F and E receptors. Expert opinion on emerging
drugs. 2016;21(1):117-128.
377. Cholkar K, Trinh HM, Pal D, Mitra AK. Discovery of novel inhibi-
tors for the treatment of glaucoma. Expert opinion on drug discov-
ery. 2015;10(3):293-313.
378. Van de Velde S, De Groef L, Stalmans I, Moons L, Van Hove I.
Towards axonal regeneration and neuroprotection in glaucoma:
Rho kinase inhibitors as promising therapeutics. Prog Neurobiol.
2015;131:105-119.
379. Schehlein EM, Novack GD, Robin AL. New classes of glaucoma
medications. Curr Opin Ophthalmol. 2017;28(2):161-168.
380. Garcia GA, Ngai P, Mosaed S, Lin KY. Critical evaluation of latano-
prostene bunod in the treatment of glaucoma. Clinical ophthalmol-
ogy (Auckland, NZ). 2016;10:2035.
381. Kaufman PL. Latanoprostene bunod ophthalmic solution 0.024%
for IOP lowering in glaucoma and ocular hypertension. Expert Opin
Pharmacother. 2017;18(4):433-444.
382. Ikuta Y, Aoyagi S, Tanaka Y, et al. Creation of nano eye-drops and ef-
fective drug delivery to the interior of the eye. Sci Rep. 2017;7:44229.
383. Tsai JC. A comprehensive perspective on patient adherence to topi-
cal glaucoma therapy. Ophthalmology. 2009;116(11):S30-S36.
384. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compli-
ance barriers in glaucoma: A systematic classification. J Glaucoma.
2003;12(5):393-398.
385. Barkana Y, Dorairaj SK, Gerber Y, Liebmann JM, Ritch R. Agree-
ment between gonioscopy and ultrasound biomicroscopy in detect-
ing iridotrabecular apposition. Arch Ophthalmol. 2007;125(10):1331-
1335.
386. Leung CK, Cheung CYL, Li H, et al. Dynamic analysis of dark–light
changes of the anterior chamber angle with anterior segment OCT.
Invest Ophthalmol Vis Sci. 2007;48(9):4116-4122.
387. WOLFF SM, ZIMMERMAN LE. Chronic secondary glaucoma.
associated with retrodisplacement of iris root and deepening of the
anterior chamber angle secondary to contusion. Am J Ophthalmol.
1962;54:547-563.
388. Campbell DG. Ghost cell glaucoma following trauma. Ophthalmol-
ogy. 1981;88(11):1151-1158.
389. Lichter PR. Iris processes in 340 eyes. Am J Ophthalmol.
1969;68(5):872-878.
390. Forbes M. Gonioscopy with corneal indentation. A method for
distinguishing between appositional closure and synechial closure.
Arch Ophthalmol. 1966;76(4):488-492.
391. Campbell DG, Vela A. Modern goniosynechialysis for the treat-
ment of synechial angle-closure glaucoma. Ophthalmology.
1984;91(9):1052-1060.
392. Greenfield DS. Glaucoma associated with elevated episcleral venous
pressure. J Glaucoma. 2000;9(2):190-194.
393. Rennie C, Chowdhury S, Khan J, et al. The prevalence and associ-
ated features of posterior embryotoxon in the general ophthalmic
clinic. Eye. 2005;19(4):396-399.
394. HENKIND P. Angle vessels in normal eyes. a gonioscopic evalua-
tion and anatomic correlation. Br J Ophthalmol. 1964;48:551-557.
395. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res.
2007;26(5):470-485.

CANADIAN JOURNAL of OPTOMETRY | REVUE CANADIENNE D’OPTOMÉTRIE VOL. 79 SUPPLEMENT 1, 2017 71